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 Abstract   
Accurate diagnosis and proper monitoring of cancer patients remain important obstacles for successful cancer tre-
atment. The search for cancer biomarkers is carried out in order to quickly identify tumor cells and predict treatment 
response, ultimately leading to a favorable therapeutic outcome.
One such prognostic marker seems to be survivin. Many studies have shown that survivin is strongly expressed in 
a vast majority of cancers. Its overexpression was demonstrated in breast and lung cancer, prostate, gastric, colon, 
bladder, and esophageal carcinomas, osteosarcomas, and lymphomas.  In many of those tumors, high activity of 
the survivin gene was associated with a poor prognosis and worse survival rates. Moreover, survivin expression was 
correlated with resistance to chemotherapy and radiotherapy-induced apoptosis. Since survivin may be identified 
as an independent prognostic factor and inhibitor of apoptosis, it may prove to be a useful therapeutic target in 
cancer therapy. 
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 Streszczenie
Trafne rozpoznanie i właściwa kontrola pacjentów z chorobami nowotworowymi są nadal jednymi z najistotniejszych 
czynników skutecznego leczenia nowotworów złośliwych u ludzi. 
Pomocnymi w szybkiej identyfikacji komórek nowotworowych i przewidywaniu ich odpowiedzi na leczenie, 
a w konsekwencji mającymi korzystny wpływ na wyniki leczenia mogą być badania skupiające się na poszukiwaniu 
markerów specyficznych dla guzów. Jednym z takich markerów prognostycznych wydaje się być surwiwina. 
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Survivin’s structure and function
Survivin	 (also	 called	 IAP	 4)	 is	 a	 protein	 with	 the	 ability	
to	 regulate	 the	 cell	 cycle	 and	 programmed	 cell	 death.	 It	 is	 the	
smallest	 member	 of	 the	 IAP	 (inhibitor	 of	 apoptosis	 protein)	
family,	 controlling	 chromosome	 compaction,	 mitotic	 spindle	
formation,	 and	 microtubule	 dynamics.	At	 the	 molecular	 level,	
survivin	 is	 a	 multifunctional	 protein	 which	 not	 only	 plays	 a	
central	 role	 in	 cell	 division,	 but	 also	 suppresses	 apoptosis	 and	
enhances	angiogenesis	[1].
Survivin	 was	 discovered	 in	 1997	 by	 Ambrosini	 and	
colleagues.	 The	 16.5	 kDa	 protein	 contains	 a	 single	 70	 amino	
acid	BIR	(baculovirus	repeat)	domain	and	an	extended	α-helical	
coiled-coil	 C-terminus.	 It	 is	 encoded	 by	 a	 single	 gene	BIRC5 
mapped	to	chromosome	17q25	[2].	
One	of	survivin’s	basic	roles	is	the	inhibition	of	apoptosis.	
It	acts	like	other	proteins	belonging	to	the	IAP	family	and	blocks	
both	 the	extrinsic	and	 intrinsic	apoptotic	pathways	by	direct	or	
indirect	 interactions	 with	 capsase-3	 and	 -7	 [1,	 2,	 3].	Another	
mechanism	of	apoptosis	inhibition	involves	preventing	the	release	
of	Smac/DIABLO	from	the	mitochondria	or	binding	directly	to	
XIAP	 (X-linked	 inhibitor	 of	 apoptosis	 protein),	 also	 known	 as	
inhibitor	of	apoptosis	protein	3	(IAP3)	[7,	8].	
Survivin	is	also	involved	in	the	regulation	of	mitosis.	This	
protein	acts	during	all	stages	of	cell	division,	 including	mitotic	
spindle	 formation	 via	 chromosome	 separation	 and	 cytokinesis.	
Subcellular	 localization	 of	 survivin	 has	 shown	 that	 the	 protein	
is	a	member	of	 the	chromosomal	passenger	complex,	which	 is	
associated	with	centromeres,	but	during	the	metaphase-anaphase	
transition	 it	 leaves	 the	 centromeres	 and	 remains	 in	 the	 spindle	
mid-zone	[4].
Survivin	has	been	shown	to	be	expressed	only	during	mitosis.	
Its	expression	increases	in	G2/M	phase	and	decreases	rapidly	in	
G1	and	its	expression	is	regulated	by	a	number	of	factors	such	as:	
E2F,	Sp1,	TCF,	and	heat	shock	protein	(Hsp)	90	[9,	10].	Survivin	
is	 also	 regulated	 by	 p53.	Wild	 type	 p53	 suppresses	 survivin’s	
expression	 at	 the	 level	 of	 mRNA,	 and	 down-regulation	 of	
survivin	by	p53	is	important	for	inducing	apoptosis.	Additionally,	
post-transcriptional	phosphorylation	has	been	proven	to	play	an	
important	regulatory	role	in	survivin	activation	[12].	
Results	of	immunohistochemical	studies	have	demonstrated	
that	in	human	cancer	cells	survivin	may	exist	in	distinct	nuclear	
and	 cytoplasmic	 subcellular	 pools.	 Its	 expression	 in	 the	 nuclei	
of	tumor	cells	appears	to	be	associated	with	unfavorable	clinical	
outcomes	[32-34].
In	 addition	 to	 the	 full-length	 transcript,	 four	 alternative	
splice	variants	of	the	survivin	gene	product	have	been	described:	
survivin-ΔEx3,	survivin-3B,	survivin-2ß	and	survivin-2α	[4].	
Previous	studies	showed	that	an	imbalance	in	the	alternative	
transcript	 ratio	may	 influence	 the	 cell’s	 apoptosis	 resistance	or	
sensitivity	[4].	
It	 has	 been	 demonstrated	 that	 the	 survivin	 transcript	 ratio	
is	also	 informative	 in	predicting	 the	response	 to	chemotherapy.	
Many	 reports	 suggest	 that	 survivin-ΔEx3	 and	 survivin-3ß	 are	
cytoprotective,	 while	 survivin-2α	 and	 survivin-2ß	 are	 pro-
apoptotic.	Survivin-ΔEx3	has	been	associated	with	higher	tumor	
staging,	increased	tumor	aggressiveness,	as	well	as	poor	prognosis	
[13].	The	 localization	 of	 the	 transcription	 variants	 of	 survivin,	
namely	survivin-2ß	and	survivin-ΔEx3,	differs.	While	survivin-
2ß	was	localized	in	both	nuclear	and	cytoplasmic	compartments,	
survivin-ΔEx3	was	found	only	in	the	nucleus	[14].
Survivin expression in premalignant lesions
Survivin	 expression	 in	 normal	 physiological	 conditions	 is	
limited	to	embryogenesis,	hematopoietic,	epithelial,	and	gonadal	
cell	lines	[11].	The	protein	is	also	detected	in	mature	tissues	with	
high	proliferation	potential	such	as	placenta,	thymus,	endothelium,	
and	CD34+	hematopoietic	progenitor	cells	[11,	24,	25].	
However	 the	 level	of	 survivin	 in	normal	 adult	 tissues	was	
shown	 to	 be	 much	 lower	 than	 in	 tumor	 tissues	 [2].	 Survivin	
transcripts	 are	 also	 commonly	 found	 in	 pre-cancerous	 lesions,	
including:	 breast	 adenomas,	Bowen	disease,	 and	 colon	polyps.	
Survivin	was	also	detected	in	breast	ductal	carcinoma	in situ	and	
cervical	intraepithelial	neoplasia	(CIN)	[26,	27].	
In	addition	to	the	increased	expression	of	survivin	observed	
in	 premalignant	 lesions,	 its	 subcellular	 localization	may	 be	 an	
important	prognostic	 factor	 as	well.	Subcellular	 localization	of	
survivin	 may	 change	 during	 malignant	 transformation	 like	 in	
the	 case	 of	 survivin’s	 cytoplasmic	 staining	 in	 non-malignant	
hepatocytes	and	its	nuclear	staining	in	hepatocellular	carcinoma	
[28].	Similarly	in	malignant	melanoma	cells,	staining	for	survivin	
was	found	only	within	the	nuclei	of	those	cells	[29].
The	 increased	 expression	 of	 survivin	 in	 a	 number	 of	 pre-
invasive	 lesions	 with	 a	 high	 predisposition	 of	 progressing	 to	
malignancy	 is	one	of	 the	reasons	 that	survivin	 is	considered	 to	
be	a	tumor	marker.
Survivin expression in cancers
Survivin	overexpression	is	observed	in	a	variety	of	cancers	
and	 correlates	 with	 an	 unfavorable	 clinical	 outcome.	 Survivin	
overexpression	was	found	in	96%	of	lung	cancer	specimens,	100%	
of	 colon	 adenocarcinomas,	 71%	 of	 prostate	 adenocarcinomas,	
80%	of	glioblastomas	and	100%	of	laryngeal	carcinomas	[5,6].	
The	activity	of	its	gene	is	also	high	in	patients	with	hematologic	
malignancies,	including	acute	leukemias	and	lymphomas	[31].	
Liczne badania wykazały między innymi, iż ulega ona silnej ekspresji w większości nowotworów złośliwych. Jej 
nadmierną ekspresję wykazano w nowotworach piersi, prostaty, żołądka, jelita grubego, pęcherza moczowego, 
raku przełyku, płuc, kostniakomięsakach oraz chłoniakach. W większości badanych przypadków wysoka aktywność 
genu surwiwiny wiązała się ze złym rokowaniem i krótszym czasem przeżycia pacjentów. 
Wykazano dodatkowo, że ekspresja surwiwiny korelowała z opornością na chemio i radioterapię, apoptozozależną. 
Od czasu kiedy surwiwina została zidentyfikowana jako niezależny czynnik prognostyczny i inhibitor apoptozy, stała 
się ona ważnym celem w terapii przeciwnowotworowej.
 Słowa kluczowe:  surwiwina / marker biologiczny guza / nowotwory / 
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Elevated	 survivin	 expression	 is	 associated	 with	
clinicopathologic	variables	of	aggressive	disease	and	correlates	
with	shorter	survival	time.	A	large	study	analyzing	275	patients	
with	 breast	 cancer	 demonstrated	 that	 survivin	 is	 a	 significant	
prognostic	 factor	 and	 predicted	 the	 outcome,	 independent	
of	 patients’	 age,	 tumor	 size	 and	 histologic	 grade	 [32].	 In	 the	
case	 of	 ovarian	 cancers,	 survivin	 expression	 correlates	 with	
the	 histological	 grading	 of	 the	 tumor	 [32].	 Moreover,	 ovarian	
carcinomas	 revealed	 that	 nuclear	 localization	 of	 survivin	
correlated	with	poor	prognostic	factors	such	as:	high	histologic	
grade,	mutant	p53,	and	poor	histologic	type	[35].
Many	 reports	 suggest	 that	 the	 differential	 localization	 of	
survivin	-	nuclear	or	cytoplasmic	-	may	reflect	different	protein	
functions.	 It	 is	 suggested	 that	 the	 nuclear	 pool	 of	 survivin	
controls	cell	division,	whereas	cytoplasmic	survivin	works	as	a	
cytoprotective	agent.	Nuclear	survivin	has	been	shown	to	be	an	
unfavorable	 prognostic	 indicator	 in	 esophageal,	 hepatocellular,	
non-small	cell	lung,	and	ovarian	cancers,	as	well	in	lymphomas	and	
endometrial	cancers	[33,	34].	In	contrast,	immunohistochemical	
analysis	 has	 revealed	 that	 cytoplasmic	 survivin	 linked	 to	 an	
anti-apoptotic	effect	has	no	prognostic	 significance.	 In	view	of	
the	data	published	thus	far,	survivin’s	role	in	various	cancers	is	
contradictive.	There	is	no	definite	explanation	for	the	differences	
observed.	However	the	simplest	one	is	based	on	the	presumption	
that	different	techniques	were	used	to	study	survivin’s	presence	
and	function.	Thus,	the	search	for	a	new	method	is	carried	out	in	
order	to	establish	the	protein’s	expression,	mechanism	of	action,	
and	correlation	with	clinical	parameters.	
Recently	the	prognostic	value	of	survivin’s	different	splice	
variants	 has	 been	 considered.	 There	 is	 conservation	 of	 anti-
apoptotic	 properties	 of	 survivin-ΔEx3	 and	 a	markedly	 reduced	
anti-apoptotic	potential	of	survivin-2B	[36].	
Loss	of	survivin-2B	expression	was	found	in	the	later	stages	
of	cancer	development,	while	survivin	and	survivin-ΔEx3	were	
not	detected,	suggesting	different	roles	of	these	variants	in	tumor	
development.	In	addition,	the	different	subcellular	localization	of	
survivin-ΔEx3	observed	in	the	nucleus,	and	survivin-2B	detected	
in	cytoplasm	seems	to	confirm	their	potential	for	different	roles.	
These	observations	indicate	that	survivin-ΔEx3	and	survivin-2B	
may	play	a	role	in	tumor	progression	and/or	tumorigenesis	[37].
	 Analysis	 of	 gastric	 cancers	 demonstrated	 that	 levels	 of	
survivin-2B	and	survivin-	ΔEx3	measured	at	the	level	of	mRNA	
possess	an	important	prognostic	value.	These	findings	may	imply	
different	 properties	 of	 survivin	 splice	 variants:	where	 the	 anti-
apoptotic	 potential	 of	 survivin-ΔEx3	 is	 preserved,	 survivin-2B	
has	 lost	 its	 anti-apoptotic	 potential	 and	may	 act	 as	 a	 naturally	
occurring	antagonist	of	the	full-length	survivin	[38].
Previous	 studies	 focused	 on	 benign	 brain	 and	 pituitary	
tumors	demonstrated	the	presence	of	survivin	in	these	tissues	[15,	
16].	Overexpression	of	survivin	was	found	in	primary	tumors	of	
the	nervous	system,	meningiomas,	and	benign	peripheral	nerve	
tumors	[30].	It	was	found	to	be	a	characteristic	feature	of	pituitary	
tumors,	 though	 survivin	 was	 also	 present	 in	 normal	 pituitary	
tissue.	 However	 the	 level	 of	 the	 gene	 expression	 was	 6-fold	
higher	 in	 tumors	 than	 in	normal	pituitary	 tissue	 [16].	All	 these	
findings	suggest	that	an	increase	in	survivin	expression	might	be	
one	of	the	factors	involved	in	pituitary	neoplastic	transformation.	
It	 was	 confirmed	 by	 further	 correlation	 between	 survivin	
overexpression	and	cell	proliferation	using	the	proliferation	ratio	
(using	the	proliferation	marker	–	PCNA)	[15].	Such	a	correlation	
was	 demonstrated	 in	 different	 tumors,	 and	 there	 was	 a	 close	
association	between	survivin	expression	and	a	high	proliferation	
index,	low	apoptotic	rate,	resistance	to	chemio-	and	radiotherapy,	
and	an	increased	percentage	of	cancer	relapse	[20,	21,	22,	23].
Thus,	survivin	represents	a	unique	target	for	biologic	therapy	
in	 many	 human	 malignancies.	 A	 number	 of	 survivin-directed	
anticancer	 therapies,	 including	 transcriptional	 repressors,	
antisense	 oligonucleotides	 (ASOs),	 hammerhead	 ribozymes,	
small	 interfering	RNAs	 (siRNAs),	 dominant-negative	mutants,	
small	 molecular	 inhibitors,	 cyclin-dependent	 kinase	 (CDK)	
inhibitors,	and	immunotherapies	are	currently	in	the	development	
stage	 [41].	 Popular	 pharmacological	 agents	 consist	 of	 histone	
deacetylase	 inhibitors,	 mitogen-activated	 protein	 kinase	 and	
cyclin-dependent	kinase	inhibitors	[39].	
It	 has	 already	 been	 reported	 that	 suppression	 of	 survivin	
expression	 using	 antisense	 oligonucleotides	 (ASO)	 induces	
tumor	cell	apoptosis	in vitro	and	in vivo	[17].	Survivin	ASOs	were	
first	 used	 against	 malignant	 melanoma	 cell	 lines.	 Transfection	
with	 the	 ASOs	 triggered	 spontaneous	 apoptosis	 linked	 to	
decreased	endogenous	survivin	expression	[41].	In	another	study	
intratumoral	injection	of	plasmids	blocking	survivin’s	expression	
stimulated	 the	 generation	 of	 tumor-specific	CTLs	 (cytotoxic	T	
lymphocytes).	This	may	be	beneficial	for	the	treatment	of	large	
lymphomas	[40].	
Many	survivin-based	vaccines	are	 in	 the	clinical	 trials	and	
peptide	vaccinations	have	been	used	in	the	treatment	of	colorectal	
and	 breast	 cancers.  Moreover,	 they	 have	 been	 well	 tolerated	
[41].
Concluding remarks 
Recent	studies	have	identified	survivin	as	a	factor	responsible	
for	cancer	progression	and	 tumor	angiogenesis.	The	prognostic	
value	 of	 survivin	 for	many	 human	 cancers	 has	 shown	 it	 to	 be	
correlated	with	an	unfavorable	clinical	outcome.	All	these	finding	
suggest	 that	 survivin	 expression	 has	 the	 potential	 for	 use	 as	 a	
predictive	biomarker	to	identify	cancer.
The	high	expression	of	 survivin	 in	cancer	cells,	with	 little	
expression	in	most	normal	tissues,	makes	survivin	an	attractive	
anticancer	 molecular	 therapeutic	 target.	 A	 wide	 variety	 of	
strategies	 have	 been	 employed	 to	 reduce	 survivin	 activity,	 and	
strong	pre-clinical	data	have	led	to	early-phase	clinical	trials	in	
which	its	effectiveness	has	been	established.	Further	investigations	
concerning	 the	 regulatory	mechanisms	of	survivin’s	expression	
and	function	in	normal	and	cancerous	cells	will	help	to	elucidate	
survivin’s	 biology	 and	 consequently	 to	 develop	 innovative	
strategies	for	selective	survivin	inhibition.
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